Healthcare Industry News: Aspect Medical Systems
News Release - February 7, 2007
Datascope Receives FDA Clearance to Include Depth-of-Anesthesia Monitoring in the Spectrum(R) OR Monitor
Strengthens Competitive Position in Operating Room MarketMONTVALE, NJ--(Healthcare Sales & Marketing Network)--Feb 7, 2007 -- Datascope Corp. (NasdaqGS:DSCP ) today announced it has received FDA clearance to include depth-of-anesthesia monitoring in its recently launched Spectrum OR monitor using Bispectral Index(TM) (BIS®) technology of Aspect Medical Systems.
The Spectrum OR monitor is designed specifically for use by the anesthesiologist in the Operating Room, and significantly increases Datascope's market opportunity in the OR. In addition to monitoring depth-of-anesthesia, and the standard range of monitored parameters, Spectrum OR also provides graphic spirometry for monitoring lung function, and new features that include quick-access trend data, optimal display visibility, and one-touch function keys.
When combined with Datascope's Gas Module SE(TM) breath-by-breath gas analyzer and Anestar Plus anesthesia delivery system, Spectrum OR provides anesthesiologists with the critical data needed for standard-of-care monitoring and anesthesia for most surgical procedures. Also, Spectrum OR interfaces with Datascope's new Viewstation OR independent display system, to provide a dedicated display for the surgeon.
"The addition of Spectrum OR to our existing Anestar Plus anesthesia delivery system will strengthen our presence in the nearly $600 million anesthesia device market," said David Gibson, president of Datascope's Patient Monitoring Division. "Spectrum OR broadens our patient monitoring product line by accommodating the requirements of all peri-anesthesia departments, including Pre-Op, Operating Room, and Recovery. Until now, Datascope has been unable to actively compete in this $100-$150 million market segment because our devices lacked the parameters and interface capabilities which are now featured in Spectrum OR. We remain committed to improving hospital care with innovative and advanced patient monitoring technologies and positioning Datascope as the premier provider for all anesthesia needs."
Spectrum OR builds on the existing Spectrum(TM) monitor platform, adding parameter capabilities used to monitor patients during anesthesia including the BIS technology and Spirometry measurement options. BIS, which measures the hypnotic state of the brain through the processing of brain waves, provides an indication of a patient's level of consciousness during monitoring and can be used to improve anesthetic delivery.
Spirometry is used to monitor a patient's lung function during ventilation. To ensure the most accurate patient data, the measurement sensor is located at the patient's airway. Spirometry data is used by the anesthesiologist to ensure optimal patient ventilation, and thereby reduce respiratory-related adverse outcomes.
About Datascope Corp.
Datascope Corp. is the global leader of intra-aortic balloon counterpulsation and a diversified medical device company that designs, manufactures and markets proprietary products for clinical health care markets in interventional cardiology and radiology, cardiovascular and vascular surgery, anesthesiology, emergency medicine and critical care. The Company has four product lines aggregated into two reporting segments, Cardiac Assist / Monitoring Products and Interventional Products / Vascular Grafts. The Company's products are sold throughout the world through direct sales representatives and independent distributors. Founded in 1964, Datascope is headquartered in Montvale, New Jersey. For news releases, webcasts and other Company information please visit Datascope's website, www.datascope.com.
This press release contains forward-looking statements that involve risks and uncertainties that could cause actual results to differ materially from those projected in the forward-looking statements. Many of these risks cannot be predicted or quantified and are at least partly outside our control, including the risk that the Spectrum OR will not significantly increase Datascope's market opportunity in the OR, that the Spectrum OR will not strengthen our presence in the nearly $600 million anesthesia device market, and that Datascope will not be positioned as the premier provider for all anesthesia needs, as well as other risks detailed in documents filed by Datascope with the Securities and Exchange Commission.
Source: Datascope
Issuer of this News Release is solely responsible for its
content.
Please address inquiries directly to the issuing company.
